NEW YORK, Jan 10 - Affymetrix and Lexicon Genetics have entered into an agreement in which Lexicon will gain broad access to Affymetrix' GeneChip arrays, instrumentation, and software, the companies said Wednesday.
Lexicon will use Affymetrix’ technology to monitor gene expression for use in its genetics and genomics R&D activities.
Financial terms of the agreement were not disclosed.
The agreement falls under Affymetrix’ BiotechAccess program, which the company is leveraging to encourage widespread adoption of its technology.
" This program makes it easy for Lexicon Genetics and other biotech companies to get cost effective access to GeneChip technology to accelerate their drug discovery and development programs, “ Gregg Fergus, vice president and general manager of the Americas at Affymetrix, said in a statement.
Lexicon will use the GeneChip technology “to share important phenotypic and expression analysis information on new and existing pharmaceutically relevant drug targets with our collaborators," said James Piggott, senior vice president of pharmaceutical biology at Lexicon.
The GeneChip system comprises disposable DNA probe arrays containing gene sequences on a chip, reagents, a scanner, instruments to process the probe arrays, and software to analyze and manage genetic information.
A spokeswoman from Affymetrix was not immediately available for comment.